Statera Biopharma, Inc. announced the closing of its previously announced underwritten public offering of 12,555,555 units, at a price to the public of $0.45 per Unit for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses.
March 24, 2022
· 5 min read